O Neil Global Advisors Inc. decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 30.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,535 shares of the company’s stock after selling 663 shares […]
Great Lakes Advisors LLC raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 0.9% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 163,485 shares of the company’s stock after purchasing an additional 1,528 shares during the period. Great Lakes Advisors LLC owned about 0.17% […]
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by investment analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Thursday. Other analysts also recently issued reports about the company. Royal Bank of Canada decreased their price target on Neurocrine Biosciences from $128.00 to $121.00 and […]
Natixis lifted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 36.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 22,426 shares of the company’s stock after acquiring an additional 6,001 shares during the period. Natixis’ holdings […]
Natixis lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 36.5% in the second quarter, according to its most recent filing with the SEC. The fund owned 22,426 shares of the company’s stock after acquiring an additional 6,001 shares during the period. Natixis’ holdings in Neurocrine Biosciences were worth $2,115,000 […]